This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. BIOA, VIRI, WHWK, PYRGF, ATNM, OSTX, EGRX, AADI, NBRV, and ELYMShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), and Eliem Therapeutics (ELYM). Alterity Therapeutics vs. Its Competitors BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada Actinium Pharmaceuticals OS Therapies Eagle Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eliem Therapeutics BioAge Labs (NASDAQ:BIOA) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Does the media refer more to BIOA or PRAN? In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. BioAge Labs' average media sentiment score of 1.87 beat Alterity Therapeutics' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Overall Sentiment BioAge Labs Very Positive Alterity Therapeutics Neutral Do institutionals and insiders hold more shares of BIOA or PRAN? 3.6% of Alterity Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is BIOA or PRAN more profitable? Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Alterity Therapeutics N/A N/A N/A Which has stronger earnings & valuation, BIOA or PRAN? Alterity Therapeutics has lower revenue, but higher earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge Labs$1.45M110.69-$71.11MN/AN/AAlterity Therapeutics$150K306.75-$6.40M-$0.70-7.39 SummaryAlterity Therapeutics beats BioAge Labs on 4 of the 6 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.01M$786.41M$5.59B$9.59BDividend YieldN/A4.84%4.71%4.03%P/E Ratio-7.391.3930.1220.53Price / Sales306.7526.21448.5398.76Price / CashN/A19.5636.0158.40Price / Book3.696.688.415.79Net Income-$6.40M-$4.14M$3.25B$259.21M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$5.17-3.2%N/A+217.9%$46.01M$150K-7.3914BIOABioAge LabsN/A$4.76+3.5%N/AN/A$164.91MN/A0.00N/AVIRIVirios TherapeuticsN/A$4.83+1.5%$5.00+3.5%+2,189.8%$93.02MN/A-17.895Upcoming EarningsGap UpWHWKWhitehawk TherapeuticsN/A$1.87+1.1%N/AN/A$87.15M$25.98M11.6940PYRGFPyroGenesis Canada0.0899 of 5 stars$0.32-0.4%N/A-53.5%$59.43M$9.14M-5.2990News CoverageGap DownHigh Trading VolumeATNMActinium Pharmaceuticals2.4309 of 5 stars$1.82+7.7%$4.00+119.8%-77.3%$56.78MN/A-1.3130News CoverageOSTXOS Therapies2.0322 of 5 stars$1.82+7.7%$18.00+889.0%N/A$51.14MN/A-2.12N/AGap UpEGRXEagle Pharmaceuticals2.4165 of 5 stars$3.69-0.3%N/AN/A$47.92M$257.55M0.00100AADIAadi Bioscience0.3856 of 5 stars$1.85+2.8%$1.67-9.9%+13.5%$45.69M$25.07M-0.8140Upcoming EarningsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ELYMEliem TherapeuticsN/A$1.51+3.4%N/A-81.4%$44.93MN/A-2.859News Coverage Related Companies and Tools Related Companies BioAge Labs Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors PyroGenesis Canada Competitors Actinium Pharmaceuticals Competitors OS Therapies Competitors Eagle Pharmaceuticals Competitors Aadi Bioscience Competitors Nabriva Therapeutics Competitors Eliem Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAN Stock Alerts